Literature DB >> 2783271

MR imaging of Parkinson disease with spin-echo and gradient-echo sequences.

B H Braffman1, R I Grossman, H I Goldberg, M B Stern, H I Hurtig, D B Hackney, L T Bilaniuk, R A Zimmerman.   

Abstract

High-field MR with both spin-echo and gradient-echo sequences was performed in 21 patients with (idiopathic, drug-responsive) Parkinson disease. The use of gradient echoes allowed more sensitive detection than did spin echoes of susceptibility changes in the putamina and substantia nigra. No statistically significant difference in putaminal hypointensity on long TR/long TE spin-echo sequences or on T2*-weighted images using gradient-echo sequences was observed between Parkinson patients and controls. There was also no statistically significant difference in the frequency of restoration of the signal intensity of the substantia nigra between the two groups of patients. The width of the pars compacta of the substantia nigra in patients with Parkinson disease was 2.12 + 0.82 mm (mean +/- SD). This value in age- and gender-matched controls was 2.67 +/- 0.5. Comparing these two groups with an unpaired t test resulted in a p value less than or equal to .005. Our MR study with spin-echo and gradient-echo images in Parkinson and control patients was able to substantiate and elaborate on previously described MR features of Parkinson disease.

Entities:  

Mesh:

Year:  1989        PMID: 2783271     DOI: 10.2214/ajr.152.1.159

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  14 in total

1.  Using high-resolution MR imaging at 7T to evaluate the anatomy of the midbrain dopaminergic system.

Authors:  M Eapen; D H Zald; J C Gatenby; Z Ding; J C Gore
Journal:  AJNR Am J Neuroradiol       Date:  2010-12-23       Impact factor: 3.825

Review 2.  Does structural neuroimaging reveal a disturbance of iron metabolism in Parkinson's disease? Implications from MRI and TCS studies.

Authors:  Adriane Gröger; Daniela Berg
Journal:  J Neural Transm (Vienna)       Date:  2012-08-09       Impact factor: 3.575

3.  Early clinical and imaging (high-field MRI) diagnosis of Hallervorden-Spatz disease.

Authors:  M Feliciani; P Curatolo
Journal:  Neuroradiology       Date:  1994-04       Impact factor: 2.804

Review 4.  Magnetic resonance imaging and magnetic resonance spectroscopy in dementias.

Authors:  Y Y Hsu; A T Du; N Schuff; M W Weiner
Journal:  J Geriatr Psychiatry Neurol       Date:  2001       Impact factor: 2.680

5.  Progressive supranuclear palsy: MRI and pathological findings.

Authors:  A Yagishita; M Oda
Journal:  Neuroradiology       Date:  1996-05       Impact factor: 2.804

6.  New MRI Biomarkers Advance the Characterization of Parkinson Disease.

Authors:  David A Ziegler; Suzanne Corkin
Journal:  Eur Neurol Rev       Date:  2013

7.  Magnetic transfer contrast accurately localizes substantia nigra confirmed by histology.

Authors:  Mark S Bolding; Meredith A Reid; Kathy B Avsar; Rosalinda C Roberts; Paul D Gamlin; Timothy J Gawne; David M White; Jan A den Hollander; Adrienne C Lahti
Journal:  Biol Psychiatry       Date:  2012-09-12       Impact factor: 13.382

8.  Computed tomography, magnetic resonance imaging and positron emission tomography with [18F]fluorodeoxyglucose in multiple system atrophy and pure autonomic failure.

Authors:  M J Fulham; R M Dubinsky; R J Polinsky; R A Brooks; R T Brown; M T Curras; S Baser; M Hallett; G Di Chiro
Journal:  Clin Auton Res       Date:  1991-03       Impact factor: 4.435

9.  Substantia nigra volume loss before basal forebrain degeneration in early Parkinson disease.

Authors:  David A Ziegler; Julien S Wonderlick; Paymon Ashourian; Leslie A Hansen; Jeremy C Young; Alex J Murphy; Cecily K Koppuzha; John H Growdon; Suzanne Corkin
Journal:  JAMA Neurol       Date:  2013-02       Impact factor: 18.302

10.  Sensitivity of T2-weighted FSE sequences towards physiological iron depositions in normal brains at 1.5 and 3.0 T.

Authors:  T Allkemper; W Schwindt; D Maintz; W Heindel; B Tombach
Journal:  Eur Radiol       Date:  2004-03-19       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.